Koichi Yanaba

ORCID: 0000-0002-3890-2830
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Systemic Sclerosis and Related Diseases
  • Inflammatory Myopathies and Dermatomyositis
  • Psoriasis: Treatment and Pathogenesis
  • Cell Adhesion Molecules Research
  • Autoimmune Bullous Skin Diseases
  • T-cell and B-cell Immunology
  • Dermatology and Skin Diseases
  • Mast cells and histamine
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Eosinophilic Disorders and Syndromes
  • Skin Diseases and Diabetes
  • Immune Cell Function and Interaction
  • Immunotherapy and Immune Responses
  • Dermatologic Treatments and Research
  • Monoclonal and Polyclonal Antibodies Research
  • Spondyloarthritis Studies and Treatments
  • Asthma and respiratory diseases
  • IL-33, ST2, and ILC Pathways
  • Autoimmune and Inflammatory Disorders Research
  • Rheumatoid Arthritis Research and Therapies
  • Systemic Lupus Erythematosus Research
  • Contact Dermatitis and Allergies
  • Immunodeficiency and Autoimmune Disorders
  • Urticaria and Related Conditions
  • Protease and Inhibitor Mechanisms

Jikei University School of Medicine
2007-2024

Katsushika Medical Center
2020

The University of Tokyo
2010-2018

Nagoya University
2018

Nagasaki University
2006-2013

University of Tennessee at Knoxville
2012

Duke University
2011

Kanazawa University
2002-2010

Duke University Hospital
2007-2010

Duke Medical Center
2006-2010

EAE is a mouse T cell–mediated autoimmune disease of the CNS used to model human condition MS. The contributions B cells initiation and progression are unclear. In this study, we have shown that differentially influenced by depletion from mice with otherwise intact immune systems. CD20 antibody–mediated cell before induction substantially exacerbated symptoms increased encephalitogenic influx into CNS. Increased symptom severity resulted rare IL-10–producing CD1dhiCD5+ regulatory subset (B10...

10.1172/jci36030 article EN Journal of Clinical Investigation 2008-09-18

Autoimmunity and inflammation are controlled in part by regulatory B cells, including a recently identified IL-10-competent CD1d(high)CD5(+) cell subset termed B10 cells that represents 1-3% of adult mouse spleen cells. In this study, pathways influence generation IL-10 production were compared with previously described predominantly the prevalent source IL-10, but not other cytokines. development and/or maturation vivo required Ag receptor diversity intact signaling pathways, T...

10.4049/jimmunol.0900270 article EN The Journal of Immunology 2009-06-03

Abstract B lymphocytes can both positively and negatively regulate cellular immune responses. Previous studies have demonstrated augmented T cell-mediated tumor immunity in genetically cell-deficient mice, suggesting that therapeutic cell depletion would enhance immunity. To test this hypothesis quantify contributions to anti-tumor responses, mature cells were depleted from wild-type adult mice using CD20 mAb prior syngeneic B16 melanoma transfers. Remarkably, s.c. volume lung metastasis...

10.4049/jimmunol.0903009 article EN The Journal of Immunology 2010-03-02

CD20 antibody depletion of B lymphocytes effectively ameliorates multiple T cell-mediated autoimmune diseases through mechanisms that remain unclear. To address this, a mouse depletes >95% mature cells in mice with otherwise intact immune systems was used to assess the role CD4 + and CD8 cell activation expansion vivo . had no direct effect on subsets or status naive mice. However, impaired clonal response protein antigens pathogen challenge, whereas not affected. In dendritic ablation,...

10.1073/pnas.0709205105 article EN Proceedings of the National Academy of Sciences 2007-12-20

Myositis-specific autoantibodies (MSAs) are a useful tool in diagnosis, defining clinical subsets and predicting prognosis of dermatomyositis (DM) polymyositis (PM). In this study, we identified novel MSA reactive with 155 140 kDa nuclear proteins [anti-155/140 antibody (Ab)] determined the feature DM patients positive for autoantibody (autoAb).Sera from 52 Japanese DM, 9 PM, 48 systemic lupus erythematosus (SLE), 126 sclerosis 18 idiopathic interstitial pneumonia were examined by...

10.1093/rheumatology/kel161 article EN Lara D. Veeken 2006-05-26

To determine serum levels of BAFF, a potent B cell survival factor, in patients with systemic sclerosis (SSc) and relate the results to clinical features SSc.Serum BAFF 83 SSc were examined by enzyme-linked immunosorbent assay (ELISA). In longitudinal study, 131 samples obtained from 21 analyzed. The expression messenger RNA (mRNA) skin was quantified real-time reverse transcription-polymerase chain reaction. receptor (BAFFR) on CD19+ cells assessed flow cytometry. production IgG...

10.1002/art.21526 article EN Arthritis & Rheumatism 2005-12-29

Abstract Mice s.c. injected with bleomycin, an experimental model for human systemic sclerosis, develop skin and lung fibrosis, which is mediated by inflammatory cell infiltration. This process highly regulated multiple adhesion molecules does not require Ag sensitization. To assess the role of in this pathogenetic process, bleomycin-induced fibrosis was examined mice lacking molecules. L-selectin and/or ICAM-1 deficiency inhibited decreased Th2 Th17 cytokines increased Th1 cytokines. In...

10.4049/jimmunol.0901778 article EN The Journal of Immunology 2010-07-12

Abstract Recent studies indicate the presence of systemic inflammation in psoriatic patients, and this inflammatory status is significantly associated with a range comorbidities. The aim study was to evaluate clinical significance novel biomarkers, neutrophil–lymphocyte ratio ( NLR ), platelet–lymphocyte PLR ) mean platelet volume MPV Japanese patients plaque‐type psoriasis (PsV) arthritis (PsA). One hundred eighty‐six PsV 50 PsA treated biologics, including infliximab, adalimumab...

10.1111/1346-8138.13875 article EN The Journal of Dermatology 2017-05-11

Rheumatoid arthritis is a systemic autoimmune disease. B cells are likely to play critical role in pathogenesis, although it unclear whether they necessary for disease induction, autoantibody production, or progression. To assess the of inflammatory arthritis, were depleted using mouse anti-mouse CD20 mAbs model collagen-induced arthritis. effectively mature from adult DBA-1 mice. When before collagen immunization, there was delay onset and with significantly diminished severity both...

10.4049/jimmunol.179.2.1369 article EN The Journal of Immunology 2007-07-15

Rapamycin, a novel macrolide immunosuppressive drug, is increasingly used as an agent for posttransplant immunosuppression and treatment of autoimmune disease. The molecular mechanism related to rapamycin-mediated that rapamycin binds FK-506 binding protein 12, the formed complex inhibits function mammalian target (mTOR), which in turn reduces phosphorylation, cell cycle progression, cytokine production. aim this study was examine effect against development fibrosis autoimmunity 2 different...

10.1002/art.27498 article EN Arthritis & Rheumatism 2010-04-07

The presence of anti-DNA topoisomerase I (anti-topo I) antibody correlates positively with disease severity in patients systemic sclerosis (SSc). However, the role induction anti-topo production and its potential contribution to pathogenesis SSc remain unclear. aim this study was examine SSc.To assess pathogenetic process, dermal sclerosis, pulmonary fibrosis, cytokine were examined mice treated topo either Freund's complete adjuvant (CFA) or incomplete (IFA).Treatment CFA, contrast...

10.1002/art.30539 article EN Arthritis & Rheumatism 2011-07-26

ABSTRACT Psoriasis is an inflammatory cutaneous disorder characterized by marked epidermal thickening and Th1 Th17 cell infiltration. At present, the contribution of B cells to pathogenesis psoriasis unclear. In mice, topical application imiquimod induces inflamed skin lesions serves as experimental animal model for human psoriasis. this study, we showed that imiquimod-induced inflammation was more severe in CD19−/− than WT mice. These responses were negatively regulated a unique...

10.1189/jlb.1112562 article EN Journal of Leukocyte Biology 2013-04-30

To clarify the clinical significance of serum levels pulmonary and activation-regulated chemokine (PARC) in diagnosis monitoring fibrosis (PF) patients with systemic sclerosis (SSc) to compare PARC KL-6 antigen or surfactant protein D (SP-D) levels.Serum were determined by enzyme-linked immunosorbent assay 123 SSc patients. In a retrospective longitudinal study, correlation activity PF was assessed 21 active PF.PARC at first visit higher than lupus erythematosus (SLE) healthy controls....

10.1002/art.21257 article EN Arthritis & Rheumatism 2005-09-01

Abstract Objective The contribution of CD19 and B lymphocytes to pulmonary fibrosis is controversial. aim this study was address the role during development fibrosis. Methods Mice lacking or overexpressing cell surface molecule CD19, which known as a positive regulator activation, were used in model bleomycin‐induced Ten sixteen days after intratracheal injection bleomycin, lung sections from mice evaluated by histologic analysis. Seven instillation, total leukocyte count number cells...

10.1002/art.23995 article EN Arthritis & Rheumatism 2008-10-30

Aberrant CD40 ligand (CD154) expression occurs on both T cells and B in human lupus patients, which is suggested to enhance cell signaling play a role disease pathogenesis. Transgenic mice expressing CD154 by their (CD154(TG)) have an expanded spleen pool produce autoantibodies (autoAbs). CD22 deficient (CD22(-/-)) also autoAbs, importantly, are hyper-proliferative following stimulation ex vivo. Combining these 2 genetic alterations CD154(TG)CD22(-/-) was thereby predicted intensify...

10.1371/journal.pone.0022464 article EN cc-by PLoS ONE 2011-07-25
Coming Soon ...